Get the Stockscreener App
106.00
0.77%
-0.82
Pre-market:
106.49
0.49
+0.46%
Haemonetics Corp stock is traded at $106.00, with a volume of 416.80K.
It is down -0.77% in the last 24 hours and down -2.21% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$106.82
Open:
$106.67
24h Volume:
416.80K
Relative Volume:
0.58
Market Cap:
$4.82B
Revenue:
$1.33B
Net Income/Loss:
$97.31M
P/E Ratio:
52.17
EPS:
2.0317
Net Cash Flow:
$260.44M
1W Performance:
-1.49%
1M Performance:
-2.21%
6M Performance:
+87.08%
1Y Performance:
+109.44%
1-Day Range:
$105.92
$108.22
1-Week Range:
$105.92
$110.45
52-Week Range:
$47.31
$110.45
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
106.00 | 4.82B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
101.07 | 174.89B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.51 | 113.22B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
269.75 | 103.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.68 | 64.75B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 49.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics Corporation (HAE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Haemonetics (HAE) Following Margin Expansion Narrative Looks Fairly Valued - simplywall.st
Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus - Yahoo Finance
HAE - Finviz
Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us
Haemonetics stock hits 52-week high at 109.6 USD By Investing.com - Investing.com South Africa
Haemonetics Shares Rise After Citigroup Upgrade - marketscreener.com
HAE Upgraded by Citigroup -- Price Target Raised to $123 - gurufocus.com
Haemonetics stock hits 52-week high at 109.6 USD - Investing.com
Haemonetics stock upgraded at Bank of America (HAE:NYSE) - Seeking Alpha
Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92 - Yahoo Finance
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - GlobeNewswire
Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure - Yahoo Finance
Haemonetics (HAE) Stock Dropped, So What Is Driving Attention Now? - simplywall.st
Q1 2027 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corporation (HAE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
HAE Maintained by Raymond James -- Price Target Raised to $125 - GuruFocus
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings - simplywall.st
Haemonetics (HAE) Q1 2027 Earnings Call Transcript - AOL.ca
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
HAE Maintained by Baird -- Price Target Raised to $119.00 - GuruFocus
Haemonetics grows recurring revenues with plasm... - Pluang
Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE) - Seeking Alpha
26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC - MarketBeat
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics stock hits 52-week high at 106.64 USD By Investing.com - Investing.com South Africa
HAE Maintains by Barrington Research -- Price Target Raised to $118 - GuruFocus
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $118 FROM $95 - Bitget
Haemonetics stock hits 52-week high at 106.64 USD - Investing.com
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating - marketscreener.com
Haemonetics Shares Hit New 52-Week High: What's Happening? - Sahm
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $118 - 富途牛牛
Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution? - simplywall.st
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors - GuruFocus
HAE Maintained by BTIG -- Price Target Raised to $110 - GuruFocus
Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets - StocksToTrade
Form 8K Haemonetics Corp For: 18 August By Investing.com - Investing.com Australia
Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook - Quiver Quantitative
HAE Looks 23.1% Overvalued on GF Value™ - GuruFocus
Haemonetics stock surges 16% on CSL Plasma supply deal By Investing.com - Investing.com Australia
Haemonetics stock surges 16% on CSL Plasma supply deal - Investing.com
HAE Looks 21.1% Overvalued on GF Value™ as Stock Surges to $104 - GuruFocus
Haemonetics (NYSE:HAE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Haemonetics (NYSE:HAE) Price Target Raised to $110.00 at BTIG Research - MarketBeat
Haemonetics Announces Non-Exclusive Supply Agreement with CSL Plasma for NexSys PCS Devices - Kalkine Media
HAE Looks 5.9% Overvalued on GF Value™ as Supply Deal with CSL P - GuruFocus
Why is Haemonetics stock surging today? - Investing.com
Why is Haemonetics stock surging today? By Investing.com - Investing.com Australia
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):